Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biotechnology AssetsXMAD:BST -5.91%19 Days Sales Outstanding is 260.78 as of Dec. 2025, which is 19% below its 10-year median of 321.05. GuruFocus rates XMAD:BST with a GF Score™ of 19/100 and a GF Value™ of €0.29 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Biotechnology Assets ranks worse than 92.98% on this metric.
The historical rank and industry rank for Biotechnology Assets's Days Sales Outstanding or its related term are showing as below:
XMAD:BST'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.08 Med: 321.05 Max: 1711.47
Current: 365.67
During the past 13 years, Biotechnology Assets's highest Days Sales Outstanding was 1711.47. The lowest was 68.08. And the median was 321.05.
XMAD:BST's Days Sales Outstanding is ranked worse than 92.98% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs XMAD:BST: 365.67
Biotechnology Assets's Days Sales Outstanding
declined
from Dec. 2024 (295.29) to Dec. 2025 (260.78).
Biotechnology Assets (XMAD:BST) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Biotechnology Assets Days Sales Outstanding Related Terms
Biotechnology Assets Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Biotechnology Assets's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Days Sales Outstanding falls into.
Biotechnology Assets Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 260.78 mean?
Biotechnology Assets (XMAD:BST) has a Days Sales Outstanding of 260.78 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Biotechnology Assets and its competitors. This is 19% below median its historical median of 321.05. Over the past decade, Biotechnology Assets' Days Sales Outstanding has ranged from 68.08 to 1,711.47. According to the industry distribution chart, Biotechnology Assets ranks #782 out of 841 companies in the Biotechnology industry, placing it in the top 93%.
Is Biotechnology Assets' Days Sales Outstanding too high?
Biotechnology Assets' current Days Sales Outstanding of 260.78 is 19% below median its 10-year median of 321.05. Over the past 10 years, this metric has ranged from a low of 68.08 to a high of 1,711.47. The Biotechnology industry median Days Sales Outstanding is 68.98. Biotechnology Assets' value of 260.78 is 278.1% above this industry median. Based on the distribution chart, Biotechnology Assets ranks #782 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #782 out of 841 companies for Days Sales Outstanding. This places Biotechnology Assets in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Biotechnology Assets' value of 260.78 is 278.1% above this benchmark. Historically, Biotechnology Assets' own Days Sales Outstanding has ranged from 68.08 to 1,711.47 over the past decade. While the company's 10-year median is 321.05 vs. the industry median of 68.98, Biotechnology Assets has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotechnology Assets's current Days Sales Outstanding of 260.78 is 278.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Biotechnology Assets and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotechnology Assets's current Days Sales Outstanding is 260.78, which is 19% below median its own 10-year median of 321.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.29, compared to a current price of €0.21 — trading 28.6% below its estimated fair value. The current Days Sales Outstanding is 260.78, which is 19% below median its 10-year median of 321.05 and 278.1% above the Biotechnology industry median of 68.98. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Days Sales Outstanding is 260.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.21 is trading 28.6% below its estimated GF Value™ of €0.29.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
Days Sales Outstanding: 260.78 (19% below median its 10-year median of 321.05)
GF Value™: €0.29 vs. price of €0.21 (28.6% below fair value)
Industry Position: 278.1% above the Biotechnology median (#782 of 841)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score
Get the complete analysis for XMAD:BST
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
